References

• 2021A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions323 cited
• 2023Trends in the approval of cancer therapies by the FDA in the twenty-first century288 cited
• 2014An overview of FDA-approved new molecular entities: 1827–2013211 cited
• 2021The Role of Real‐World Evidence in FDA‐Approved New Drug and Biologics License Applications172 cited
• 2023Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy133 cited
• 2020Use of Real-World Evidence to Support FDA Approval of Oncology Drugs121 cited
• 2021Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study112 cited
• 2020Me‐too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists94 cited
• 2022Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-201983 cited
• 2021Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–202071 cited
• 2020Project Orbis: Global Collaborative Review Program68 cited
• 2006An update on the first decade of the European centralized procedure: how many innovative drugs?68 cited
• 2013What matters most in commercial success: first-in-class or best-in-class?